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Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease
2019 (COVID-19), has resulted in an ongoing pandemic. Presently, there are no clinically approved drugs for
COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. Herein, we
discovered Clioquinol (5-chloro-7-iodo-8-quinolinol (CLQ)), a Food and Drug Administration (FDA) approved
drug, and two of its analogues (7-bromo-5-chloro-8-hydroxyquinoline (CLBQ14); and 5, 7-Dichloro-8-hydroxyquinoline (CLCQ)) as potent inhibitors of SARS-CoV-2 infection-induced cytopathic effect in vitro. In addition, all
three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin-converting
enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein. CLQ displayed the highest potency in the low micromolar range, with its antiviral activity showing a strong correlation
with inhibition of rhACE2 and rhACE2-RBD interaction. Altogether, our ﬁndings provide a new mode of action
and molecular target for CLQ and validates this pharmacophore as a promising lead series for the clinical
development of potential therapeutics for COVID-19.

1. Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a
novel RNA betacoronavirus, is the causative agent for coronavirus disease 2019 (COVID-19), which has emerged as an ongoing pandemic
(World Health Organization, 2020a). Worldwide, SARS-CoV-2 has
spread rampantly to more than 192 countries/regions and has resulted in
105,097,000 conﬁrmed cases, 58,465,536 recovered, including 2,289,
979 deaths (Johns Hopkins Center for Systems Science and Engineering,
Coronavirus resource center). Within the United States alone, there are
more than 26,716,484 cases and a total of 458,105 deaths as of February
5, 2021, according to the Johns Hopkins COVID-19 dashboard. About
80% of people infected with SARS-CoV-2 experience mild symptoms or
are asymptomatic (World Health Organization, 2020b). A majority of
symptomatic patients with moderate to severe symptoms have shown a
broad range of clinical manifestation and/or signiﬁcant complications,
including severe pneumonia, multi-organ failure, acute cardiac injury,
neurological damage, septic shock, acute respiratory distress syndrome
(ARDS) (Zhu et al., 2020; Huang et al., 2020; Madjid et al., 2020; Mao

et al., 2020). Recent reports revealed that individuals with pre-existing
medical conditions have increased risk of COVID-19 related morbidity
and mortality (Guan et al., 2020). Currently, there are no U.S. Food and
Drug Administration (FDA) approved drugs for the treatment of
COVID-19; but several studies are investigating the potential utility of
repurposing clinically approved drugs as treatment options for COVID-19
(National Institute of Health (NIH), 2020; Sanders et al., 2020; Slomski,
2020; Horby et al., 2020; Verma et al., 2020). To date, only Remdesivir,
an inhibitor of RNA-dependent RNA Polymerase, has been granted
emergency use authorization (EUA) for the treatment of hospitalized
patients with severe cases of COVID-19 (Food and Drug Administration
(FDA), 2020).
Historically, Clioquinol (5-chloro-7-iodo-8-quinolinol (CLQ)) and its
derivatives belonging to the 8-hydroxyquinoline structural class has
shown potent broad-spectrum activity against clinically relevant pathogens (You et al., 2018; Bednarz-Prashad and John, 1983; Auld et al.,
1974; Olaleye et al., 2011; Darby and Nathan, 2010; Tavares et al., 2018;
Bohlmann et al., 2018). More recently, CLQ and its analogues have been
extensively investigated as potential treatments for cancer and
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their effects on the exopeptidase activity of rhACE2. Herein, we discovered for the ﬁrst time that CLQ, CLBQ14, and CLCQ effectively inhibits
the novel SARS-CoV-2 infection-induced CPE in vitro, inhibited rhACE2,
and its interaction with the Spike protein and rhACE2 exopeptidase activity in the low micromolar range. Thus, rapid optimization and preclinical development of CLQ and its congeners could potentially accelerate their consideration for repurposing as potential antiviral agents
against COVID19, ﬁrst in non-human primate (NHP) models of SARSCoV-2 infection, and subsequently in clinical trials.

neurodegenerative diseases (Schimmer et al., 2012; Ayton et al., 2015;
Tavares et al., 2020; Cherny et al., 2012; Lannfelt et al., 2008; Ritchie
et al., 2003; Adlard et al., 2008; Shi et al., 2020). Additional studies have
also shown the involvement of CLQ in the efﬂux mechanisms of ATP
binding cassette (ABC) transporters (Perez et al., 2019; McInerney et al.,
2018) and the cellular autophagic pathway (Yu et al., 2009; Ding et al.,
2005), a critical process in the host defense machinery against viral infections (Choi et al., 2018). Furthermore, using a high-throughput screen
(HTS) and chemical genomics approach, Olaleye, O., et al. identiﬁed and
characterized CLQ and certain analogues as potent inhibitors of methionine aminopeptidase (Olaleye et al., 2011), a universally conserved
metalloprotease required for N-terminal methionine excision (Lowther
and Matthews, 2000; Giglione et al., 2003). As an established metal
chelator and Zinc ionophore, CLQ modulates underlying molecular and
physiologic machinery required for metal homeostasis (Yu et al., 2009;
Ding et al., 2005, 2008; Haase et al., 2008; Lind et al., 2009; Andersson
et al., 2009). Altogether, these pharmacologic properties of CLQ make it
an attractive drug for potential targeting of angiotensin-converting
enzyme 2 (ACE2).
ACE2 is a Zinc metalloprotease and essential cellular receptor for
SARS-CoV-2 entry into host cells (Wrapp et al., 2020; Yan et al., 2020;
Wang et al., 2020; Walls et al., 2020). Therefore, rapid identiﬁcation of
potent and selective ACE2 inhibitors have the prospects of accelerating
the clinical development of preventative interventions and/or treatment
options for COVID-19. ACE2 is mainly expressed in alveolar epithelial
cells of the lungs, heart, kidney, and gastrointestinal tract (Hamming
et al., 2004; Harmer et al., 2002). Although ACE2 is the cellular receptor
for SARS-CoV-2 (Wrapp et al., 2020; Yan et al., 2020; Wang et al., 2020;
Walls et al., 2020); ACE2 primarily functions as a carboxypeptidase that
catalyzes the conversion of a single residue from angiotensin (Ang II),
generating L-phenylalanine and Ang (1–7), a potent vasodilator, thus
playing a critical role in controlling hypertension, renal disease, cardiac
function and lung injury (Warner et al., 2003; Kuba et al., 2005). The
crystalline structure of the ACE2 shows two domains; an N-terminal Zinc
metallopeptidase domain (MPD) capable of binding the viral
envelope-anchored Spike (S) glycoprotein of coronaviruses and a C terminal “collectrin-like” domain (Towler et al., 2004; Li et al., 2005; Li,
2015). The interaction of the MPD of ACE2 and S glycoprotein of
SARS-CoV-2 is the initial and critical step in viral infection by receptor
recognition and fusion of host and viral cellular membranes 2 (Wrapp
et al., 2020; Yan et al., 2020; Wang et al., 2020; Walls et al., 2020). In
addition, viral entry requires priming of S protein by a host protease into
S1 and S2 subunits, which are responsible for receptor attachment and
membrane fusion, respectively (Song et al., 2018; Kam et al., 2009;
Hoffmann et al., 2020; Belouzard et al., 2009). A receptor-binding
domain (RBD) of the S1 subunit speciﬁcally recognizes ACE2 on
human cells (Wrapp et al., 2020; Yan et al., 2020; Wang et al., 2020;
Walls et al., 2020). Binding of the S1 subunit to ACE2 receptor triggers a
conformational change in S glycoprotein from metastable pre-fusion state
to stable post-fusion conformation, resulting in shedding of S1 and
transition of the S2 subunit to expose a hydrophobic fusion peptide
(Wang et al., 2020; Kirchdoerfer et al., 2016; Gui et al., 2017). The initial
priming at S1/S2 boundary promotes subsequent cleavage at the S2 site
by host proteases, which is critical for membrane fusion and viral
infectivity (Belouzard et al., 2009; Millet and Whittaker, 2015; Madu
et al., 2009). Therefore, targeting the interaction between the human
ACE2 receptor and the RBD in the S protein of SARS-CoV-2 could serve as
a promising approach for the development of effective entry inhibitors
for potential prevention and/or treatment of COVID-19.
In this study, we evaluated the effect of CLQ and two of its analogues
(7-bromo-5-chloro-8-hydroxyquinoline (CLBQ14); and 5, 7-dichloro-8hydroxyquinoline (CLCQ)) on SARS-CoV-2 infection-induced cytopathic effect (CPE) in vitro. In addition, we assessed the cytotoxicity of
these compounds. Furthermore, we determined the impact of all three
compounds on recombinant human ACE2 (rhACE2) interaction with the
RBD on the Spike protein of SARS-CoV-2; and independently assessed

2. Materials and methods
2.1. Materials
2.1.1. Cell growth conditions and medium
African Green Monkey Kidney Vero E6 cells (ATCC# CRL-1586,
American Tissue Culture Type) were maintained using medium purchased from Gibco (modiﬁed eagle's medium (MEM) Gibco (#11095);
10% fetal bovine serum (HI FBS) Gibco (#14000); Penicillin/Streptomycin (PS) Gibco (#15140); 10U/mL penicillin and 10 μg/mL streptomycin (only in assay media)). For the SARS-CoV-2 infection-induced
cytopathic effect (CPE) assay, cells were grown in MEM/10% HI FBS and
harvested in MEM/1% PS/supplemented with 2% HI FBS. Cells were
batch inoculated with SARS-CoV-2 USA_WA1/2020 (M.O.I. ~ 0.002),
which resulted in 5–10% cell viability 72 h post-infection.
2.1.2. Compounds and preparation of stock solutions
The small molecule inhibitors, 5-chloro-7-iodo-8-quinolinol (Clioquinol, CLQ; C0187-Lot JJ01 SPGN), and 7-bromo-5-chloro-8-hydroxyquinoline (CLBQ14; B1190-P61JD-FD)); were purchased from TCI
America.
5,
7-dichloro-8-hydroxyquinoline
(CLCQ;
D64600Lot#STBH7389) and Zinc Chloride (ZnCl2; 208086-Lot#MKCL1763)
were purchased from Sigma Aldrich. We prepared 10mM stock solutions of the inhibitors in Dimethyl sulfoxide (DMSO; D8418Lot#SHBL5613) purchased from Sigma Aldrich. For the CPE assay,
compound samples were serially diluted 2-fold in DMSO nine times and
screened in duplicates. Assay Ready Plates (ARPs; Corning 3764BC) predrugged with test compounds (90nL sample in 100% DMSO per well
dispensed using a Labcyte (ECHO 550) are prepared in the Biosafety
Level-2 (BSL-2) laboratory by adding 5μL assay media to each well.
2.1.3. Method for measuring the antiviral effect of CLQ, CLBQ14, and
CLCQ
The SARS-CoV-2 infection-induced cytopathic effect (CPE) assay and
cytotoxicity assays were generated and performed through a sub-contract
to Southern Research Institute (SRI), Birmingham, Alabama from Texas
Southern University, Houston, Texas. The CPE reduction assay was
conducted at SRI to screen for antiviral agents in high throughput
screening (HTS) format as previously described (Maddox et al., 2008;
Severson et al., 2007). Brieﬂy, Vero E6 cells selected for expression of the
SARS-CoV-2 receptor (ACE2; angiotensin-converting enzyme 2) are used
for the CPE assay. Cells were grown in MEM/10% HI FBS supplemented
and harvested in MEM/1% PS/supplemented with 2% HI FBS. Cells were
batch inoculated with SARS-CoV-2 (M.O.I. ~ 0.002), which resulted in
5% cell viability 72 h post infection. Compound samples were serially
diluted 2-fold in DMSO nine times and screened in duplicates. Assay
Ready Plates (ARPs; Corning 3764 BC black-walled, clear bottom plates)
pre-drugged with test compounds (90nL sample in 100% DMSO per well
dispensed using a Labcyte (ECHO 550) were prepared in the BSL-2 laboratory by adding 5μL assay media to each well. The plates were passed
into the BSL-3 facility, where a 25μL aliquot of virus inoculated cells
(4000 Vero E6 cells/well) was added to each well in columns 3–22. The
wells in columns 23–24 contained virus infected cells only (no compound
treatment). Prior to virus infection, a 25μL aliquot of cells was added to
columns 1–2 of each plate for the cell only (no virus) controls. After
incubating plates at 37 C/5%CO2 and 90% humidity for 72 h, 30μL of
2

O.A. Olaleye et al.

Heliyon 7 (2021) e06426

and 0.1μM for CLQ, CLBQ14, and CLCQ. All experiments were performed
in triplicates. Each plate contained positive controls (1% DMSO) and
blank controls with no ACE2. Brieﬂy, 1μL of serially diluted compounds
were incubated with recombinant SARS-CoV-2 Spike receptor binding
domain (RBD) protein, pre-coated on the 96 well plates in 49μL of 1X
assay diluent buffer for 31 min, at room temperature (22 C) with shaking
at 180rpm. Next, we added 50μL of ACE2 protein in 1X assay diluent
buffer into the 96 well plate and incubated for 2.5 h at room temperature
(22  C) with shaking at 180rpm. Thereafter, the solution was discarded
and the plate was washed four times with 300μL of 1X wash buffer,
followed by the addition of the detection antibody (anti-ACE2 goat
antibody). The reaction was allowed to go on for 1 h at room temperature
(22 C) with shaking at 180rpm. Then, the solution was discarded, and
the wash step was repeated as described above. Next, the HRPconjugated anti-goat IgG was added to each well, and the reaction
plate was further incubated for 1 h at room temperature (22 C) with
shaking at 180rpm. Again, the solution was discarded, and the wash step
was repeated as described above. Then, 100μL of 3,30 ,5,50 -tetramethylbenzidine (TMB) one-step substrate was added to each well, and the
reaction mixtures were incubated in the dark at room temperature (22 C)
with shaking at 180rpm for an additional 30 min and then stopped by the
addition of 50μL stop solution. The absorbance was read at 405nm using
a Beckman Coulter DTX880 multimode plate reader. The background
hydrolysis was subtracted, and the data were ﬁtted to a special bellshaped dose-response curve equation using GraphPad prism software
8.4.3.

Cell Titer-Glo (Promega) was added to each well. Luminescence was read
using a PerkinElmer Envision or BMG CLARIOstar plate reader following
incubation at room temperature for 10 min to measure cell viability. Raw
data from each test well was normalized to the average (Avg) signal of
non-infected cells (Avg Cells; 100% inhibition) and virus infected cells
only (Avg Virus; 0% inhibition) to calculate % inhibition of CPE using the
following formula: % inhibition ¼ 100*(Test Cmpd - Avg Virus)/(Avg
Cells – Avg Virus). IC50 values and curves were obtained using non-linear
regression. The SARS CPE assay was conducted in BSL-3 containment
with plates being sealed with a clear cover and surface decontaminated
prior to luminescence reading. Reference compounds for CPE assay were
made available by SRI.
2.1.4. Method for measuring the cytotoxic effect of CLQ, CLBQ14, and
CLCQ
Compound cytotoxicity was assessed in a BSL-2 counter screen as
follows using the Cell Titer-Glo Luminescent Cell Viability Assay (Severson et al., 2007). Host cells in media were added in 25μl aliquots (4000
cells/well) to each well of assay ready plates prepared with test compounds as above. Cells only (100% viability) and cells treated with
hyamine at 100μM ﬁnal concentration (0% viability) serve as the high
and low signal controls, respectively, for cytotoxic effect in the assay.
DMSO was maintained at a constant concentration for all wells (0.3%) as
dictated by the dilution factor of stock test compound concentrations.
After incubating plates at 37 C/5%CO2 and 90% humidity for 72 h, 30μl
CellTiter Glo (CTG) (G7573, Promega) was added to each well. Luminescence was read using a BMG CLARIOstar plate reader following incubation at room temperature for 10 min to measure cell viability.

3. Results

2.1.5. ACE2 inhibitor screening assay
An ACE2 Inhibitor screening assay kit with a ﬂuorogenic substrate
(Catalogue #79923) was purchased from BPS Bioscience (San Diego, CA)
and adapted to measure the exopeptidase activity of ACE2 in the presence and absence of inhibitors. The Fluorescence assay was performed
using a black ﬂat-bottom 96-well plate with a ﬁnal reaction volume of
50μL following the manufacturer's instructions. We prepared 10mM
stock solutions of the compounds in Dimethyl sulfoxide (DMSO). Next,
we serially diluted the compounds in DMSO as follows: 100, 50, 10, 1,
0.5, and 0.1μM for CLQ and CLBQ14; as well as 10 μM, and 1μM for
CLCQ. All experiments were performed in triplicates. Each plate contained a positive control of enzyme-treated with vehicle alone (2%
DMSO), and a blank control with no enzyme. Brieﬂy, each reaction
contained 24μL of puriﬁed recombinant human ACE2 protein (0.42ng/
μL) in ACE2 buffer, 1μL of compound at serially diluted concentrations,
and 25μL ACE2 ﬂuorogenic substrate. The total reaction volume was
50μL. The reaction mixtures were protected from light and incubated for
2.5 h at room temperature (22 C). Thereafter, the ﬂuorescence intensities (λExcitation ¼ 535nm, λEmission ¼ 595nm) were measured using a
Beckman Coulter DTX880 multimode plate reader. A similar experiment
was conducted to measure and compare the exopeptidase activity of
ACE2 in the presence and absence of Zinc Chloride (ZnCl2) alone,
CLBQ14 alone, and ZnCl2 in combination with CLBQ14 at concentrations
ranging from 100μM to 100nM. ZnCl2 was serially diluted in water, and a
positive control of enzyme-treated with vehicle alone (water for ZnCl2
only; DMSO for CLBQ14 alone; and water plus DMSO for ZnCl2 and
CLBQ14) was carried out for this experiment. The background hydrolysis
was subtracted, and the data were ﬁtted to a four-parameter logistic
(variable slope) equation using GraphPad prism software 8.4.3.

3.1. Efﬁcacy of Clioquinol (CLQ) and analogues against SARS-CoV-2
infection -induced cytopathic effect (CPE) in Vero E6 cells
In our efforts to identify inhibitors of SARS-CoV-2 infection for the
potential treatment of COVID-19, we evaluated the in vitro antiviral activity of CLQ, and two of its derivatives, CLBQ14 and CLCQ, using a
standard luminescent-based high-throughput screening (HTS) platform
(Maddox et al., 2008; Severson et al., 2007) for SARS-CoV-2 infection-induced CPE in African Green Monkey Kidney Vero E6 cells. We found
that all three compounds inhibited SARS-CoV-2 infection-induced CPE in
vitro with 50% Inhibitory Concentration (IC50) values in the low micromolar concentration (Figure 1). Amongst all three analogues tested, CLQ
displayed the most potent antiviral activity in the CPE assay (Figure 1).
Compared to its counterparts, CLBQ14 exhibited the highest maximum
inhibition at about 102.96% inhibition at 30μM (Table 1). In addition,
we compared the antiviral effects of CLBQ14 and its analogues with ﬁve
other known inhibitors of SARS-CoV-2 in vitro: Chloroquine, Hydroxychloroquine, Remdesivir, Aloxistatin and Calpain Inhibitor IV (Figure 2).
The dose-response curves of the CLQ, CLBQ14, CLCQ and the reference
compounds mentioned above were determined at multiplicities of
infection (MOI) of about 0.002 (Figure 2). We found that the IC50 for CLQ
(12.62μM), and its analogues [(CLBQ14, 14.69μM) and (CLCQ,
16.30μM)] were slightly lower than the IC50 of Aloxistatin (16.72μM);
but moderately higher than Chloroquine (1.10μM), Hydroxychloroquine
(5.04μM), Remdesivir (4.42μM), and Calpain Inhibitor IV (0.41μM)
(Table 2). These results suggest a potentially new mechanism of action
for CLQ and its congeners. Notably, this is the ﬁrst report to our
knowledge, revealing that CLQ and its analogues effectively inhibit the
novel SARS-CoV-2 infection-induced CPE.

2.1.6. The ACE2-Spike (RBD) protein interaction assay
A Spike-ACE2 binding assay kit (Cat # CoV-SACE2-1, Lot# 062320
7066) was purchased from RayBiotech (Norcross, GA). The in vitro
enzyme-linked immunoabsorbent assay (ELISA) was adapted and performed in a transparent ﬂat-bottom 96-well plate. We prepared 10mM
stock solutions of the compounds in Dimethyl sulfoxide (DMSO), with
serially diluted the compounds in DMSO as follows: 100, 50, 10, 5, 1, 0.5,

3.2. Cytotoxicity effects of CLQ and analogues in Vero E6 cells
We determined the preliminary cytotoxicity of CLQ and its analogues
(CLBQ14 and CLCQ), using a Cell Titer-Glo Luminescent Cell Viability
Assay (Severson et al., 2007). We assessed the cytotoxic effects of the
various compounds in Vero E6 cells and observed that, the 50% cytotoxic
concentration (CC50) of CLQ and its derivatives were all greater than
3

O.A. Olaleye et al.

Heliyon 7 (2021) e06426

Figure 1. Efﬁcacy of Clioquinol (CLQ) and Analogues against SARS-CoV-2 induced Cytopathic Effect (CPE) in Vero E6 cells: A. CLBQ14, B. CLCQ, and C. CLQ.

30μM. However, in comparison to the other reference compounds tested,
CLQ and its analogues displayed lower percent minimum viability at
higher concentrations. On the other hand, we observed similar percent
maximum viability for CLQ pharmacophore and the other reference
compounds at lower concentrations (Table 3). This suggests that, the
cytotoxic effects may not be a concern at lower concentrations of CLQ

and its analogues. Additional concentrations need to be tested in future
studies to determine the actual CC50 value (Table 3).
3.3. Effects of CLQ and its analogues on rhACE2 exopeptidase activity
We determined the effect of CLQ, CLBQ14 and CLCQ on the
exopeptidase activity of rhACE2 using an adapted ﬂuorometric assay

Table 1. Chemical Structure and Activity of Clioquinol (CLQ) and Analogues against SARS-CoV-2 induced Cytopathic Effect (CPE) in Vero E6 Cells.
Inhibitor ID

Screen ID

IC50 (μM)

Maximum Inhibition at 30μM (%)

CLBQ14

MDXC19T001

14.69

102.96

CLCQ

MDXC19T002

16.30

89.78

CLQ

MDXC19T003

12.62

91.78

Chemical Structure
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Figure 2. Efﬁcacy of Reference Inhibitors against SARS-CoV-2 induced Cytopathic Effect (CPE) in Vero E6 cells: A. Calpain Inhibitor IV, B. Chloroquine, C Remdesivir,
D. Hydroxychloroquine, and E. E64d (Aloxistatin).

activity of rhACE2 in the presence of Zinc Chloride (ZnCl2) alone,
CLBQ14 alone and ZnCl2 in combination with CLBQ14 at concentrations
ranging from 100μM to 100nM. In the presence of ZnCl2 alone, rhACE2
displayed increasing exopeptidase activity. On the other hand, in the
presence of ZnCl2 in combination with CLBQ14, we observed an
increased shift in IC50 value by over 28 fold compared to CLBQ14 alone
(Figure 3). Interestingly, this data reveals that increasing concentrations
of ZnCl2 titrates the inhibitory effect of CLBQ14 on rhACE2 from

(BPS Bioscience). We found that all three compounds inhibited rhACE2
activity with similar IC50 values in the low micromolar concentration,
with CLQ being the most potent amongst all three analogues tested at
IC50 of 5.36μM (Table 4). To our knowledge, these results revealed for
the ﬁrst time that rhACE2 is a biochemical target of CLQ and its analogues. Because the known metal cofactor for ACE2 is Zinc (Towler et al.,
2004; Vickers et al., 2002), using the same ﬂuorometric assay described
above in the methods section, we further assessed the exopeptidase

Table 2. Chemical Structure and Activity of Reference Inhibitors against SARS-CoV-2 induced Cytopathic Effect (CPE) in Vero E6 Cells.
Inhibitor ID

Screen ID

IC50 (μM)

Maximum Inhibition (%)

Concentration at Maximum % Inhibition (μM)

Calpain Inhibitor IV

AB01968659

0.41

95.75

7.17

Chloroquine

AB00053436

1.10

111.08

7.50

Remdesivir

AB01952209

4.42

100.27

15.00

Hydroxychloroquine

AB00053257

5.04

93.14

30.00

E64d (Aloxistatin)

AB01955411

16.72

98.55

30.00

Chemical Structure
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Table 3. Cytotoxicity of Clioquinol (CLQ) and analogues in Vero E6 cells, in comparison to reference inhibitors of SARS-CoV-2.
Inhibitor ID

Cytotoxicity
CC50 (μM)

Minimum
Viability (%)

Concentration at
Minimum % Viability (μM)

Maximum
Viability (%)

Concentration at
Maximum % Viability (μM)

CLBQ14

>30.00

53.50

15.00

107.88

0.12

CLCQ

>30.00

60.82

15.00

101.51

0.06

CLQ

>30.00

61.83

30.00

105.82

0.23

Calpain Inhibitor IV

>7.17

98.29

3.59

104.99

0.22

Chloroquine

>30.00

95.63

15.00

106.60

0.06

Remdesivir

>30.00

97.49

3.75

104.49

0.06

Hydroxychloroquine

>30.00

96.88

3.75

103.65

0.06

E64d (Aloxistatin)

>30.00

100.06

15.00

112.76

0.12

Table 4. Activity of Clioquinol (CLQ) and analogues against ACE2 exopeptidase activity and ACE2 and SARS-CoV-2 Spike (RBD) protein interaction.
Inhibitor ID

IC50 (μM)
ACE2 Exopeptidase Activity Assay

Spike (RBD)-ACE2 Interaction Assay (IC50_1 (μM))

Spike (RBD)-ACE2 Interaction Assay (IC50_2 (μM))

CLBQ14

5.55

2.76

3.06

CLCQ

<10

1.74

1.91

CLQ

5.36

0.85

18.15

*CLBQ14 and ZnCl2

159.00

ND

ND

*ZnCl2

ND

ND

ND

*

Higher Concentrations need to be conducted to determine IC50.

concentrations ranging from above 5–10μM, consistent with previous
reports of the required optimal concentration range of Zinc for the
exopeptidase activity of ACE2 (Vickers et al., 2002). Taken together,
these preliminary results reveal a new pharmacologic mode of action and
novel target for CLQ and its analogues.

to higher concentrations (Figure 4). The bell-shaped curve generated two
IC50 values (IC50_1 and IC50_2), as shown in Table 4. We found that all
three compounds had similar IC50 values in the low micromolar concentration ranging from 0.85μM to 2.76μM for IC50_1; however, CLQ
displayed a higher IC50_2 at 18.15μM (Table 4). The unconventional dose
response curve observed in this interaction assay could be an indicator of
additional binding site(s) and/or target(s) for the CLQ pharmacophore,
such as other sites on ACE2 or the Spike (RBD) protein. Again, these
ﬁndings are the ﬁrst report to reveal that CLQ and its analogues inhibit
and interfere with the binding between human ACE2 receptor and
SARS-CoV-2 Spike RBD protein in vitro. These results suggest that the
CLQ and its derivatives might be promising leads for the clinical development of novel SARS-CoV-2 entry inhibitors and potential COVID-19
therapeutics.

3.4. Effects of CLQ and its analogues on rhACE2 and Spike (RBD) protein
interaction
The interaction of the human ACE2 receptor with SARS-CoV-2's Spike
protein receptor binding domain is a critical ﬁrst step in the process
required for viral entry into host cells (Wrapp et al., 2020; Yan et al.,
2020; Wang et al., 2020; Walls et al., 2020). Using an adapted in vitro
enzyme-linked immunoabsorbent assay (ELISA) (RayBiotech, 2020), we
evaluated the effect of CLQ, CLBQ14 and CLCQ on the binding afﬁnity of
rhACE2 and RBD of the S protein at concentrations ranging from 100μM
to 100nM. Surprisingly, we observed a unique bell-shaped dose-response
curve for all three compounds with higher inhibition of ACE2-Spike
(RBD) protein interaction at lower compound concentrations compared

4. Discussion
Given the ongoing COVID-19 pandemic and the emerging virulence
of novel SARS-CoV-2 strains, there is an urgent need to accelerate the
development of effective therapeutic agents as countermeasures against
this pathogen. In this study, we applied three independent approaches to
investigate the possibility of CLQ and its analogues as potential inhibitors
of the SARS-CoV-2 infection in vitro and gathered strong evidence that
these pharmacophores are promising leads for the discovery and preclinical development of novel SARS-CoV-2 entry inhibitors and potential COVID-19 therapeutics. To our knowledge, this is the ﬁrst report
revealing rhACE2 as a novel target for CLQ and its analogues, a new
pharmacologic mode of action for an old antibacterial. Taken together,
our in vitro ﬁndings that CLQ signiﬁcantly inhibited the binding of
rhACE2 receptor with SARS-CoV-2 Spike (RBD) protein and SARS-CoV-2
infection-induced CPE, strongly supports the notion that CLQ and its
congeners could be potential drugs and/or chemical probes in the
development of countermeasures against viral entry into host cells.
The availability of simple, rapid, cellular high throughput screening
and well-characterized biochemical assays enabled us to quickly discover
novel inhibitors of SARS-CoV-2 infection in vitro. We successfully identiﬁed and characterized CLQ, a known metal chelator, and Zinc ionophore as a novel inhibitor of SARS-CoV-2 infection-induced CPE. Using
two structural analogues of CLQ (CLBQ14 and CLCQ) in hand, we were

Figure 3. Effect of Clioquinol (CLQ) and Analogues against ACE2 Exopeptidase
Activity: A. CLBQ14 (Circles - red), B. CLQ (Squares - green), and C. ZnCl2
(Triangle – blue), and D. CLBQ14 and ZnCl2 (Inverted Triangles – magenta).
6

O.A. Olaleye et al.

Heliyon 7 (2021) e06426

Figure 4. Inhibition of ACE2 and SARS-CoV-2 Spike (RBD) protein interaction by Clioquinol (CLQ) and analogues: A. CLBQ14, B. CLCQ, and C. CLQ.

the nanomolar range (unpublished data). Therefore, additional in vivo
cytotoxicity studies for Vero E6 cells should be conducted at a wider
range of concentrations.
Throughout our study, we consistently observed a correlation between the high potency of CLQ compared to its other two analogues in
the antiviral screen, inhibition of rhACE2 metalloprotease activity, and
its ability to disrupt the binding of rhACE2 with SARS-CoV-2 Spike (RBD)
protein. Amongst all three compounds, CLQ displayed the highest potency in all three independent assays, except for IC50_2, hence validating
its potential as a therapeutic option for the treatment of COVID-19.
Clioquinol and its derivatives belonging to 8-hydroxyquinoline structural
class have been investigated extensively in basic, translational, and
clinical studies because of their multiple activities as metal chelators and
Zinc ionophores, modulating underlying molecular and physiologic
switches required for metal homeostasis in vivo (You et al., 2018; Bednarz-Prashad and John, 1983; Auld et al., 1974; Olaleye et al., 2011;
Darby and Nathan, 2010; Tavares et al., 2018, 2020; Bohlmann et al.,
2018; Schimmer et al., 2012; Ayton et al., 2015; Cherny et al., 2012;
Lannfelt et al., 2008; Ritchie et al., 2003; Adlard et al., 2008; Shi et al.,
2020; Perez et al., 2019; McInerney et al., 2018; Yu et al., 2009; Ding
et al., 2005) Haase et al., 2008; Lind et al., 2009; Andersson et al., 2009;
Ding et al., 2008). Previously, CLQ was used to treat bacterial infections
(Cahoon, 2009); however, it was withdrawn from the clinic because of
untoward effects of subacute myelo-optic neuropathy (SMON) mostly
experienced in Japan in the 1950's (Perez et al., 2019; Cahoon, 2009;
Kono, 1971). More recent studies revealed that SMON might be due to
other biologic factors and/or pharmacogenetics primarily linked to the
Japanese population (Perez et al., 2019; Cahoon, 2009; Meade, 1975).
Currently, in the clinic, CLQ is approved for use in combination with
other agents for the treatment of inﬂammatory skin disorders and fungal
infections in some countries (You et al., 2018; Mao and Schimmer, 2008).
More recently, CLQ and its newer structural derivatives have gained

able to further explore the impact of the active CLQ pharmacophore on
the novel coronavirus infection, the exopeptidase activity of rhACE2, and
the interaction of rhACE2 with SARS-CoV-2 Spike (RBD) protein, all
critical steps/processes in the pathogenesis of COVID-19. All three analogues displayed similar potent inhibition in the low micromolar range
against SARS-CoV-2 infection-induced CPE, rhACE2 activity, and its
interaction with Spike protein. In this study, we also compared the doseresponse curves of antiviral effects of CLQ and its analogues with ﬁve
other known inhibitors of SARS-CoV-2 in vitro: Chloroquine, Hydroxychloroquine, Remdesivir, Aloxistatin, and Calpain Inhibitor IV and found
that CLQ's potency was better and comparable to Aloxistatin; but had
lower efﬁcacy than the other reference inhibitors (Table 2). It is important to note that the Vero E6 cells used for the SARS-CoV-2 infectioninduced CPE assay were ﬁrst sorted by ﬂow cytometry by SRI for selection of cells that had higher levels of ACE2 expression to increase the
efﬁciency of infection. Therefore, the observed IC50 values may be higher
than the actual IC50 values in cells that do not have high levels of ACE2
expression. Moreover, we observed that the IC50 values of the compounds
in the biochemical assays were much lower than the IC50 in the cellular
antiviral assay. We also assessed the cytotoxic effects of the compounds
in Vero E6 cells and observed that CLQ and its analogues displayed lower
percent minimum viability at higher concentrations compared to the
other reference compounds tested. However, we observed similar
percent maximum viability for CLQ pharmacophore and the other
reference compounds at lower concentrations (Table 3). This suggests
that the cytotoxic effects may not be a concern at lower concentrations of
CLQ and its analogues. In addition, the observed IC50 values for inhibition of rhACE2 exopeptidase activity and rhACE2-RBD interaction were
in the low micromolar range, suggesting that we may need lower concentrations for in vivo activity. Furthermore, we have other preliminary
cytotoxicity results from prior in vivo studies on CLQ and its analogues
that reveal no signiﬁcant toxicity at much lower concentrations below
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cautiously when targeting ACE2 (South et al., 2020); without permanently inactivating its exopeptidase or other cellular functions to avoid
potential adverse effects to the heart and/or lung function. Our lead
compound CLQ is a weak metal chelator and Zinc ionophore that can
shuttle free Zinc across the membrane (Yu et al., 2009; Colvin et al.,
2008). Because of these properties, CLQ may temporarily or reversibly
affect ACE2 function and prevent its interaction with SARS-CoV-2 RBD
protein; without permanently inhibiting its essential exopeptidase function. Because rhACE2 is a novel host target for CLQ and its analogues, the
potential effect of CLQ inhibition on heart and lung function needs to be
further explored in vivo and pre-clinical studies.
The crystal structure of full-length human ACE2 revealed that the RBD
on SARS-CoV-2 S1 binds directly to the metallopeptidase domain (MPD) of
the ACE2 receptor (Wrapp et al., 2020; Yan et al., 2020), which consists of
amino acid residues that coordinate Zinc, providing further support for the
utility of Zinc chelators and/or ionophores such as CLQ and its congeners,
as promising inhibitors of interaction and viral entry inhibitors. Using a
sensitive ELISA, we found that CLQ and its analogues potently disrupt the
interaction of ACE2 and Spike (RBD) protein, with CLQ being the most
potent. This supports our ﬁndings that CLQ and its derivatives bind to
ACE2 and inhibits its exopeptidase activity. Interestingly unlike the CLQ
pharmacophore, other studies revealed that (S,S)-2-{1-Carboxy-2-[3-(3,
5-dichloro-benzyl)-3H-imidazol-4-yl]-ethylamino}-4-methyl-pentanoic
acid (MLN-4760), a known potent inhibitor of ACE2 exopeptidase activity,
belonging to a different chemical class, does not disrupt ACE2-Spike
interaction in coronaviruses, SARS-CoV, SARS-CoV2, and NL63S (Nami
et al., 2020; Mathewson et al., 2008) as its binding site on ACE2 is different
from the site where RBD interacts with ACE2 (Towler et al., 2004; Nami
et al., 2020; Li et al., 2005). However, CLQ seems to affect ACE2 by
reversibly chelating its Zinc ion, which is essential for ACE2 activity, as
well as interfere with ACE2-RBD interaction. Although Zinc is essential for
stabilizing protein structures and altering the substrate afﬁnity of different
metalloproteins (Ding et al., 2005; Cox and McLendon, 2000), the effects
of Zinc chelation on the molecular structure of ACE2 and its effects on its
binding to the SARS-CoV-2 remains to be tested. Moreover, earlier molecular and structural studies also revealed that mutations in the catalytic
site required for exopeptidase activity of ACE2 had no effect on Spike RBD
binding to ACE2 (Towler et al., 2004). Howbeit, the unconventional
dose-response bell shaped curve that we observed in our studies suggests
that there may be additional binding sites and/or modes of action for CLQ
and its congeners, resulting in the potent inhibition of interaction at lower
micromolar concentrations; compared to higher concentrations. Although
CLQ was found to be the most potent amongst all 3 analogues, except for
IC50_2, preliminary structure activity relationship studies (SAR) revealed
that the other two derivatives are comparable to CLQ, as they both show
potent inhibition of rhACE2-RBD interaction, as well as inhibition of
antiviral and anti-rhACE2 activity. Therefore, providing alternative analogues that might not have the same adverse effects experienced with CLQ
in the past, potentially alleviating some of the concerns with CLQ. Additional biochemical and structural studies are required to explore other
possible mechanisms of action such as competition or interaction of CLQ
with RBD for binding to the MPD of ACE2, thereby preventing Zinc chelation and ionophore activity of CLQ. Future X-ray structures could help to
better understand the mode of inhibition of this pharmacophore and the
rational design of more potent drugs.
The strength of our study includes the use of a rapid multi-prong
approach via three sensitive independent assays to identify and characterize an existing clinical drug as a novel inhibitor of SARS-CoV-2
infection in vitro. In addition, the availability of structural analogues of
CLQ, made possible a preliminary SAR, which revealed similarity between the IC50 values of CLQ and its structural analogues. However, our
study has some limitations, such as the use of Vero E6 cells that were
selected for high expression of ACE2 in the antiviral assay, a HTS
designed to rapidly screen for inhibitors of infection-induced CPE. An
additional limitation is that the amount of Zinc in the puriﬁed rhACE2
supplied from BPS and RayBiotech assays was unknown. Future metal

renewed interest as potential drugs for the development of therapeutics
for neurodegenerative diseases, cancer, and infectious diseases (You
et al., 2018; Bednarz-Prashad and John, 1983; Auld et al., 1974; Olaleye
et al., 2011; Darby and Nathan, 2010; Tavares et al., 2018, 2020; Bohlmann et al., 2018; Schimmer et al., 2012; Ayton et al., 2015; Cherny
et al., 2012; Lannfelt et al., 2008; Ritchie et al., 2003; Adlard et al., 2008;
Shi et al., 2020; Perez et al., 2019; McInerney et al., 2018; Yu et al., 2009;
Ding et al., 2005) Haase et al., 2008; Lind et al., 2009; Andersson et al.,
2009; Ding et al., 2008). Furthermore, in previous studies, Olaleye O.
et al., serendipitously discovered CLBQ14, the bromine analogue of CLQ,
and characterized CLQ and additional derivatives as potent inhibitors of
replicating and non-replicating Mycobacterium tuberculosis, using an HTS
assay designed to identify novel metalloprotease inhibitors (Olaleye
et al., 2011). Altogether, the plethora of evidence on the broad pharmacologic spectrum of activity and metal-chelation propensity of CLQ
pharmacophore, combined with its extensive clinical investigational
proﬁle, makes this structural class attractive and promising for targeting
ACE2, the important Zinc metalloenzyme and essential cellular receptor
for SARS-CoV-2 entry into host cells (Wrapp et al., 2020; Yan et al., 2020;
Wang et al., 2020; Walls et al., 2020).
ACE2, a carboxypeptidase, is a known type I integral membrane
protein made up of about 805 amino acids belonging to the large family
of Zinc metalloproteases with a high level of structural homology for a
catalytic motif, containing one characteristic HEXXH þ E Zinc-binding
consensus sequence and binding sites for inhibitor or speciﬁc substrates respectively (Towler et al., 2004). According to earlier reports by
Towler et al. the ﬁrst crystalline structures of the metallopeptidase
domain of ACE2 revealed “a large inhibitor-dependent hinge bending
movement of one catalytic subdomain relative to the other that brings
important amino acid residues into position for catalysis,” similar to
observed subdomains on other Zinc metalloproteases respectively
(Towler et al., 2004). The residues critical for coordinating the binding of
Zinc to ACE2 are His374, His378, and Glu402, according to earlier x-ray
structures (Towler et al., 2004). Moreover, ACE2 is activated by monovalent anions and is also known to contain an inhibitor-speciﬁc anion
binding site (Towler et al., 2004; Vickers et al., 2002). The reported
optimal metalloprotease activity of recombinant soluble human ACE2
was found to be in the presence of 10μM ZnCl2 (Vickers et al., 2002). This
is consistent with our ﬁndings of rhACE2 exopeptidase activity assay in
the presence of ZnCl2. In the presence of the newly identiﬁed potent
metalloprotease inhibitors (CLQ or CLBQ14 alone), we observed a
signiﬁcantly decreased exopeptidase activity for ACE2 in the low
micromolar concentrations (Figure 4). However, we found an increased
shift in IC50 values when we assessed exopeptidase activity in the presence of ZnCl2 in combination with CLBQ14 by over 28 fold compared to
CLBQ14 alone (Figure 3), suggesting that CLBQ14 might be working
through Zinc chelation, interaction and/or coordination. Our ﬁndings
not only revealed a novel target (rhACE2) and mechanism of action for
the CLQ pharmacophore; but also provides insight into potential
reversibility of inhibition and one or more probable mode(s) of inhibition: 1) The concentration of CLBQ14 is titrated with excess ZnCl2, thus
pre-occupied and unavailable to inhibit rhACE2 exopeptidase activity;
and/or 2) potential competition for the similar binding sites on rhACE2.
Additional mechanistic kinetic studies will be required to ascertain these
notions.
Moreover, as mentioned earlier, ACE2 plays an essential role in the
regulation of cardiovascular and respiratory physiology (Kuba et al.,
2005; Towler et al., 2004). Its characterization as the functional host
receptor for entry of the novel SARS-CoV-2 into human cells (Wrapp
et al., 2020; Yan et al., 2020; Wang et al., 2020; Walls et al., 2020) has
raised concerns about the potential impact of newly discovered ACE2
inhibitors on cardiovascular and respiratory physiology (South et al.,
2020; Nishiga et al., 2020; Imai et al., 2005). Recent studies have also
shown that ACE2 plays a key role in protecting the lungs from ARDS
(Nishiga et al., 2020; Imai et al., 2005), a severe complication of
COVID-19 disease (Huang et al., 2020). Therefore, one has to proceed
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interactions (Zhang et al., 2017; Capel et al., 2015; Plasencia-Garcia
et al., 2020; Roden et al., 2020) encountered with other drugs.

dependent studies with apoenzymes will be required to determine the
amount of Zinc. Considering that CLQ is a known Zinc chelator and
ionophore, an understanding of the physiologic amount of Zinc required
for inhibition will be critical for optimal efﬁcacy. Therefore, for these two
limitations, the measured IC50 values for the compounds may not be
representative of the actual in vitro IC50, which may be lower. However,
the remarkable consistency in the observed strong correlation between
CLQ, and its congener's antiviral activity, in vitro rhACE2, inhibition and
disruption of ACE2-RBD protein interaction, reduce these concerns.
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5. Conclusion and signiﬁcance
The impact of the COVID-19 pandemic on human health, healthcare
systems, and the global economy (Chaudhry et al., 2020) has imposed an
urgent call/pressing need for the development of novel antivirals. Rapid
clinical development of anti-COVID19 treatments could be accelerated
by the discovery of repurposed clinically approved drugs with new
mechanisms of action and/or multiple cellular targets that could potentially disrupt viral pathogenesis/survival and/or prevent the viral
entry/interaction with host receptor ACE2. The body of evidence on the
broad pharmacologic spectrum of activity, metal-chelation propensity,
and Zinc ionophore activity of CLQ pharmacophore, combined with its
extensive clinical investigational proﬁle, makes this structural class
attractive and promising drugs for targeting rhACE2. Using a multi-prong
approach, we discovered and characterized CLQ, a clinical drug, and two
of its analogues (CLBQ14 and CLCQ) as potent inhibitors of SARS-CoV-2
infection-induced CPE in vitro; rhACE2 metalloprotease activity; and the
binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein. Altogether,
these novel ﬁndings provide insights into a new mode of action and
molecular target(s) for CLQ and its derivatives. Thus, validating this
structural class as promising leads for clinical development of novel
SARS-CoV-2 entry inhibitors and potential COVID-19 therapeutics.
Because rhACE2 is a host target, it reduces the concerns for the development of drug resistance, which is usually seen with drugs that target
viral genes. Further SAR, computational/molecular modeling, and
X-crystal structure studies will aid the rational design and synthesis of
more potent inhibitors in the CLQ-containing, 8-hydroxylquinoline
structural class. Our studies not only provide an additional new drug
class with Zinc chelating and ionophore properties in the pipeline for the
urgent quest for therapeutic management for anti-COVID-19 but also
suggests that there could be the potential physiologic relevance of Zinc
homeostasis in SARS-CoV-2 infection and COVID-19 pathogenesis. In
addition, CLQ and its derivatives could be used as chemical probes to
study the biology of host-pathogen interaction in the context of
SARS-CoV-2 infections. In the future, the functional importance of molecular and cellular regulation of host and viral Zinc-dependent genes/proteins in SARS-CoV-2 pathogenesis and survival may be better
understood and targeted with available Zinc chelators, ionophores, and
transporters. Moreover, unlike MLN-4670, another known ACE2 inhibitor (Towler et al., 2004; Nami et al., 2020; Mathewson et al., 2008), our
results not only show that CLQ and its analogues inhibit rhACE2 with
antiviral activity but also suggests that CLQ pharmacophore, potently
disrupts the interaction of rhACE2 and Spike (RBD) protein. To this end,
we provide strong cellular and biochemical evidence supporting the
notion that CLQ, CLBQ14, and CLCQ, could serve as a potential lead
series for the pre-clinical development of new anti-COVID-19 treatments.
The expectation is that the development of new anti-COVID-19 treatments with dual activity against viral and host entry target could help
combat the issue of emerging drug-resistant strains, drug-drug interactions, reduction in the cost of treatment, possibly increase patient
compliance and improve patient care as well as reduce the mortality rate
due to SARS-CoV-2 infection. Therefore, we propose pharmacologic and
clinical studies to further explore CLQ and/or its derivatives as treatment
options in the toolbox for combating this novel coronavirus and be
evaluated in conjunction with other available therapeutics to reduce
COVID-19 morbidity and mortality as well as a potential drug to drug
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